Form 4: Waystar Holding Corp. Director Priscilla Hung Reports Stock and Option Grants

Director Priscilla Hung reports receiving stock options and restricted stock units in Waystar Holding Corp.

Summary

• On June 10, 2024, Priscilla Hung, a director of Waystar Holding Corp., reported the acquisition of 8,695 shares of common stock through a grant of restricted stock units (RSUs).
• These RSUs vest on the earlier of June 6, 2025, or the first regularly scheduled annual meeting of stockholders following the grant date.
• Each RSU represents the right to receive one share of common stock upon settlement.
• Hung also holds 24,200 stock options with an exercise price of $37.2, granted on February 1, 2024, which vest in three equal annual installments starting February 1, 2025.
• The reported transactions reflect a 0.605-for-1 reverse stock split effective May 15, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grants align director interests with shareholders, but there are no immediate financial implications.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule of the RSUs and stock options encourages long-term commitment from the director.

Future Outlook

The director's holdings will increase as the RSUs and stock options vest over time, aligning her interests with the company's long-term performance.

Industry Context

Stock grants and options are common forms of executive compensation in publicly traded companies, used to incentivize performance and retain key personnel. The specific terms of these grants, such as vesting schedules and exercise prices, are tailored to the company's specific circumstances and compensation philosophy.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages across the tech and healthcare industries, often benchmarked against peer companies like Veeva Systems, Cerner (now Oracle Health), and Teladoc Health.
• The vesting schedules, typically three to four years, are also in line with industry norms to ensure long-term alignment with company goals.
• The size of the grant, relative to the director's existing holdings and the company's overall equity pool, would need to be compared against similar companies to assess its competitiveness and potential impact on shareholder dilution.

Stakeholder Impact

• Shareholders: The grants align the director's interests with those of the shareholders, potentially leading to better company performance.
• Employees: The grants can boost employee morale by demonstrating that the company is investing in its leadership.

Key Dates